A Retospective Case-Control Study to Estimate the Sensitivity and Specificity of a Pharmacogenetic Marker (HLA-B5701) in subjects with and without Hypersensitivity to Abacavir

Grants and Contracts Details

StatusFinished
Effective start/end date12/1/068/31/11

Funding

  • GlaxoSmithKline: $9,444.00